NUS sci­en­tists har­ness AI plat­form for ad­vanced can­cer

BioSpectrum (Asia) - - Q & A -

A trans­la­tional re­search team led by Na­tional Univer­sity of Sin­ga­pore (NUS) has har­nessed CU­RATE.AI, a pow­er­ful ar­ti­fi­cial in­tel­li­gence (AI) plat­form, to suc­cess­fully treat a pa­tient with ad­vanced can­cer, com­pletely halt­ing dis­ease pro­gres­sion. This new de­vel­op­ment rep­re­sents a big step for­ward in per­son­al­ized medicine. Dur­ing the clin­i­cal study, a pa­tient with metastatic cas­tra­tion-re­sis­tant prostate can­cer (MCRPC) was given a novel drug com­bi­na­tion con­sist­ing of in­ves­ti­ga­tional drug ZEN-3694 and en­za­lu­tamide, an ap­proved prostate can­cer drug. The re­search team suc­cess­fully uti­lized CU­RATE.AI to con­tin­u­ously iden­tify the op­ti­mal doses of each drug to re­sult in a durable re­sponse, al­low­ing the pa­tient to re­sume a com­pletely nor­mal and ac­tive life­style. Ac­cord­ing to the sci­en­tific team, CU­RATE.AI is ap­pli­ca­ble to all dis­eases and all pa­tients, and a first gen­er­a­tion of the plat­form was pre­vi­ously val­i­dated in the clinic for sin­gle drug op­ti­miza­tion in post-trans­plant im­muno­sup­pres­sion. This new study demon­strates that CU­RATE.AI can op­ti­mize multi-drug reg­i­mens. The CU­RATE.AI team ex­pects to broadly de­ploy the plat­form for the pre­ven­tion of trans­plant re­jec­tion, adult and pe­di­atric can­cers, car­dio­vas­cu­lar medicine, di­a­betes man­age­ment, in­fec­tious dis­eases, and many other ap­pli­ca­tions.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.